Infection Requiring Hospitalization
There were 118 episodes of infective complications requiring hospitalization. More than 60% of them (i.e., 73 cases) occurred during the first 12 months of biological therapy. 
Demographic Data
Up to May 2017, a total of 3,838 courses of biologics were used in 2,399 patients (1,396 women and 1,003 men) with various rheumatic diseases. The mean age at commencement of treatment was 46.9 (range 1-89) years. More than half of the patients suffered from rheumatoid arthritis, while the others were mainly patients with ankylosing spondylitis and psoriatic arthritis (Figures 1-3 ). Other indications of the biologics are shown in Table 1 . The longest duration of therapy was 162 months.
Co-morbid Conditions
The most common coexisting medical conditions of patients using biological agents were hypertension (18.4%), diabetes mellitus (7.4%), peptic ulcer (4.3%), depression (4.3%), and fatty liver (4.3%). Other comorbid conditions reported were chronic hepatitis B infection (4.0%), previous pulmonary tuberculosis (TB) (3.8%), liver disease (2.6%), renal disease (2.5%), asthma (2.5%), hyperthyroidism (2.0%), ischemic heart disease (2.0%), cancer (1.6%), stroke (1.2%), congestive heart failure (0.7%), heart attack (0.6%), epilepsy (0.6%), previous extra-pulmonary TB (0.5%), Chronic obstructive airway disease (COAD) (0.5%), chronic hepatitis C infection (0.4%), and demyelination (0.04%).
Tuberculosis
A total of 59 cases of TB were reported: 31 related to infliximab, 12 related to etanercept, 9 related to adalimumab, 4 related to golimumab, and 3 related to tocilizumab. Nearly 40% of the TB cases (i.e., 23 cases) occurred during the first 6 months of treatment. There were 465 abnormal chest radiographs before treatment, and isoniazid chemoprophylaxis was given to 768 patients with latent TB as defined by either positive MT2 (≥10 mm induration) or a positive Interferon gamma release assay. 
